The DOI matches its Crossref record.
Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Molecular pathogenesis of sporadic colon cancer and colon cancer associated with inflammatory bowel disease. Many of the genetic alterations associated with development of sporadic colon cancer also play a role in colitis associated colon cancer. However, the frequency and sequence of these events differ between the cancers. Modified from Ref [21]. APC: Adenomatous polyposis coli; MSI: Microsatellite instability; KAS : Kirsten Rat Sarcoma Viral Oncogene Homolog; COX-2: Cyclooxygenase-2; DCC: Deleted in colorectal carcinoma; DPC4: Deleted in pancreatic carcinoma 4; CIN: Chromosomal instability.](/paper-figures/86bf99a4373c4d928e110e155b5034a8/colorectal-cancer-in-inflammatory-bowel-disease-the-risk-pathogenesis-prevention-figure-1.png)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The development of IBD‐related colorectal cancer (CRC), chronic inflammation is a major risk factor for gastrointestinal malignancies development in IBD patients.”
From Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer (2021) · cites this paper as [139]
Experimental — accuracy not yet measuredIn the citing paper
“There has been evidence over the decade that show a link between chronic intestinal inflammation and CRC thorough a series of events; from the development of early dysplasia to low grade dysplasia to high‐grade dysplasia to eventually converting to invasive adenocarcinoma.”
From Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer (2021) · cites this paper as [139]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 98
- 10.1002/jso.21505 · DOI
- 10.1053/j.gastro.2005.12.037 · DOI
- 10.1002/ibd.21365 · DOI
- 10.1111/j.1572-0241.2006.00520.x · DOI
- Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-535. · DOI
- Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004;2:1088-1095. · DOI
- Kim BJ, Yang SK, Kim JS, Jeen YT, Choi H, Han DS, Kim HJ, Kim WH, Kim JY, Chang DK. Trends of ulcerative colitis-associated colorectal cancer in Korea: A KASID study. J Gastroenterol Hepatol 2009;24:667-671. · DOI
- Söderlund S, Brandt L, Lapidus A, Karlén P, Broström O, Löfberg R, Ekbom A, Askling J. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009;136:1561-157; quiz 1818-9. · DOI
- 10.1111/j.1365-2036.2006.02854.x · DOI
- Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 2008;14:3937-3947. · DOI
- 10.1038/ajg.2013.249 · DOI
- 10.5009/gnl.2008.2.2.61 · DOI
- 10.1056/nejm199011013231802 · DOI
- 10.1097/01.MIB.0000217770.21261.ce · DOI
- 10.1002/hep.24247 · DOI
- 10.1136/gut.2004.046615 · DOI · Paper page
- Olsson R, Danielsson A, Järnerot G, Lindström E, Lööf L, Rolny P, Rydén BO, Tysk C, Wallerstedt S. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991;100:1319-1323. · DOI
- Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56:48-54. · DOI · Paper page
- Nuako KW, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, Lindor NM. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology 1998;115:1079-1083. · DOI
- Askling J, Dickman PW, Karlén P, Broström O, Lapidus A, Löfberg R, Ekbom A. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001;120:1356-1362. · DOI
- 10.1053/j.gastro.2011.01.057 · DOI
- 10.1152/ajpgi.00079.2004 · DOI
- Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-459. · DOI · Paper page
- 10.1053/j.gastro.2007.08.001 · DOI
- 10.1053/j.gastro.2006.03.028 · DOI
- 10.1097/MEG.0b013e32835b5803 · DOI
- Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res 2009;29:2727-2737.
- 10.1016/j.coph.2009.06.006 · DOI
- Befrits R, Hammarberg C, Rubio C, Jaramillo E, Tribukait B. DNA aneuploidy and histologic dysplasia in long-standing ulcerative colitis. A 10-year follow-up study. Dis Colon Rectum 1994;37:313-319; discussion 319-320. · DOI
- Willenbucher RF, Zelman SJ, Ferrell LD, Moore DH, Waldman FM. Chromosomal alterations in ulcerative colitis-related neoplastic progression. Gastroenterology 1997;113:791-801. · DOI
- Hardy RG, Meltzer SJ, Jankowski JA. ABC of colorectal cancer. Molecular basis for risk factors. BMJ 2000;321:886-889. · DOI
- Itzkowitz S. Colon carcinogenesis in inflammatory bowel disease: applying molecular genetics to clinical practice. J Clin Gastroenterol 2003;36:S70-S74; discussion S94-96. · DOI
- Aust DE, Terdiman JP, Willenbucher RF, Chang CG, Molinaro-Clark A, Baretton GB, Loehrs U, Waldman FM. The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer 2002;94:1421-1427. · DOI
- Tarmin L, Yin J, Harpaz N, Kozam M, Noordzij J, Antonio LB, Jiang HY, Chan O, Cymes K, Meltzer SJ. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res 1995;55:2035-2038.
- 10.1007/s13402-010-0006-4 · DOI
- 10.1200/jco.2007.10.9744 · DOI
- Schulmann K, Mori Y, Croog V, Yin J, Olaru A, Sterian A, Sato F, Wang S, Xu Y, Deacu E. Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. Gastroenterology 2005;129:74-85. · DOI
- Fleisher AS, Esteller M, Harpaz N, Leytin A, Rashid A, Xu Y, Liang J, Stine OC, Yin J, Zou TT. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res 2000;60:4864-4868.
- Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M, Porschen R. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res 1998;58:3942-3945.
- Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997;39:1-20. · DOI
- Elzagheid A, Emaetig F, Alkikhia L, Buhmeida A, Syrjänen K, El-Faitori O, Latto M, Collan Y, Pyrhönen S. High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer. Anticancer Res 2013;33:3137-3143.
- 10.1146/annurev.pharmtox.42.082301.164620 · DOI
- 10.1016/s0002-9440(10)64587-7 · DOI
- 10.1038/ejhg.2010.159 · DOI
- 10.1152/ajpcell.00422.2001 · DOI
- Klaunig JE, Xu Y, Isenberg JS, Bachowski S, Kolaja KL, Jiang J, Stevenson DE, Walborg EF. The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect 1998;106 Suppl 1:289-295. · DOI
- Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000;60:3333-3337.
- Kimura H, Hokari R, Miura S, Shigematsu T, Hirokawa M, Akiba Y, Kurose I, Higuchi H, Fujimori H, Tsuzuki Y. Increased expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. Gut 1998;42:180-187. · DOI
- Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z, Podolsky DK. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn’s disease. Gut 1995;36:718-723. · DOI
- Actis GC, Tarallo S, Rosina F. Cutting edge: chemoprevention of colorectal neoplasia in inflammatory bowel disease. Inflamm Allergy Drug Targets 2013;12:1-7. · DOI
- 10.1016/s0002-9440(10)61172-8 · DOI
- 10.1172/jci118861 · DOI
- O’Mahony L, Feeney M, O’Halloran S, Murphy L, Kiely B, Fitzgibbon J, Lee G, O’Sullivan G, Shanahan F, Collins JK. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 2001;15:1219-1225. · DOI
- 10.1053/j.gastro.2008.02.012 · DOI
- Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994;107:117-120. · DOI
- 10.1016/j.bpg.2011.09.003 · DOI
- 10.1111/j.1572-0241.2005.41442.x · DOI
- 10.1002/ibd.20074 · DOI
- 10.1038/ajg.2011.50 · DOI
- 10.1136/gut.2011.237412 · DOI
- Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997;112:29-32. · DOI
- Matula S, Croog V, Itzkowitz S, Harpaz N, Bodian C, Hossain S, Ullman T. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 2005;3:1015-1021. · DOI
- 10.3748/wjg.v18.i29.3839 · DOI
- 10.1053/gast.2003.50156 · DOI
- Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95. · DOI
- 10.1038/ajg.2011.156 · DOI
- Biasco G, Di Marco MC. Folate and prevention of colorectal cancer in ulcerative colitis. Eur J Cancer Prev 2005;14:395-398. · DOI
- Baggott JE, Morgan SL, Ha T, Vaughn WH, Hine RJ. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem J 1992;282:197-202. · DOI
- Reisenauer AM, Halsted CH. Human jejunal brush border folate conjugase. Characteristics and inhibition by salicylazosulfapyridine. Biochim Biophys Acta 1981;659:62-69. · DOI
- Diculescu M, Ciocîrlan M, Ciocîrlan M, Piţigoi D, Becheanu G, Croitoru A, Spanache S. Folic acid and sulfasalazine for colorectal carcinoma chemoprevention in patients with ulcerative colitis: the old and new evidence. Rom J Gastroenterol 2003;12:283-286.
- 10.1038/ajg.2010.428 · DOI
- Takashi H, Tmomyuki K, Yukihide K. Colorectal cancer in patients with inflammatory bowel disease in Japan. Stomach Intestine 2002;37:887-893.
- 10.1097/MIB.0b013e3182802c6a · DOI
- 10.1002/14651858.CD000279.pub3 · DOI
- 10.1002/14651858.CD000279.pub2 · DOI
- 10.1136/gut.2010.225466 · DOI
- 10.1016/j.crohns.2007.12.001 · DOI
- 10.1053/j.gastro.2009.12.035 · DOI
- 10.1038/ajg.2009.727 · DOI
- 10.5946/ce.2012.45.3.274 · DOI
- 10.1038/ajg.2011.93 · DOI
- Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR, Rabinovitch PS. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992;103:1611-1620. · DOI
- 10.1053/j.gastro.2007.01.048 · DOI
- 10.1053/j.gastro.2005.12.035 · DOI
- 10.1016/j.gie.2009.05.010 · DOI
- van Rijn AF, Fockens P, Siersema PD, Oldenburg B. Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn’s colitis patients in the Netherlands. World J Gastroenterol 2009;15:226-230. · DOI
- Eaden JA, Ward BA, Mayberry JF. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc 2000;51:123-128. · DOI
- 10.4253/wjge.v4.i4.108 · DOI
- 10.1111/apt.12508 · DOI
- Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB, Talbot IC. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 2004;53:256-260. · DOI
- 10.1111/j.1572-0241.2008.01934.x · DOI
- 10.1053/gast.2003.50146 · DOI
- 10.1055/s-2007-966214 · DOI
- 10.1055/s-0030-1255956 · DOI
- 10.1038/ajg.2012.67 · DOI
- 10.1136/gut.2007.131359 · DOI
- Messmann H, Endlicher E, Freunek G, Rümmele P, Schölmerich J, Knüchel R. Fluorescence endoscopy for the detection of low and high grade dysplasia in ulcerative colitis using systemic or local 5-aminolaevulinic acid sensitisation. Gut 2003;52:1003-1007. · DOI
- 10.1136/gut.2007.144097 · DOI
Cited by
Sorted by citations
Xia, T., Konno, H., Ahn, J., & Barber, G. N. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.029 · Cited by 589
Modulation of inflammation by autophagy: Consequences for human disease
Netea-Maier, R. T., Plantinga, T. S., van de Veerdonk, F. L., Smit, J. W., & Netea, M. G. (2016) · Autophagy · doi:10.1080/15548627.2015.1071759 · Cited by 349
Hypoxia-inducible factors: a central link between inflammation and cancer
Triner, D., & Shah, Y. M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84430 · Cited by 199
Constante, M., Fragoso, G., Calvé, A., Samba-Mondonga, M., & Santos, M. M. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01809 · Cited by 161
Metabolomic analysis in inflammatory bowel disease: A systematic review
Gallagher, K., Catesson, A., Griffin, J. L., Holmes, E., & Williams, H. R. T. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjaa227 · Cited by 133
Metadata
- Authors
- Kim, E. R.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2014
- Volume
- 20
- Issue
- 29
- Pages
- 9872
- ISSN
- 1007-9327
- Cited by
- 357
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis. https://app.cochat.ai/papers/10.3748/wjg.v20.i29.9872
- The paper
- Kim, E. R. (2014). Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis. World Journal of Gastroenterology. https://doi.org/10.3748/wjg.v20.i29.9872